Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2009. InterMune reported a net loss for the second quarter of 2009 of $36.7 million, or $0.81 per share, compared with a net loss of $29.6 million, or $0.76 per share, in the second quarter of 2008.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "The last several months have been exceptionally productive for InterMune and the coming months promise to be even more so. Regarding pirfenidone, we have made excellent progress on the preparation of our New Drug Application (NDA) for pirfenidone which we now expect to submit in the fourth quarter. It has taken more time than we anticipated to integrate the advice of a host of external expert advisors and to take every possible step to develop the strongest possible file that positions us for potential approval in the first review cycle. Our Marketing Authorization Application (MAA) is also progressing very well; we had a successful pre-submission meeting with the EMEA in July and we expect to submit the MAA for pirfenidone in the first quarter of 2010."

Mr. Welch continued, "Regarding ITMN-191 (R7227), we announced exciting news today on several important aspects of the program, specifically: the successful completion of six-month and nine-month chronic toxicology studies in rats and monkeys, respectively which clear the way for our Phase 2 and Phase 3 clinical programs; our expectation that our partner Roche will enroll the first patient in our Phase 2b study of ITMN-191 in combination with standard of care in August; our plans to start a Phase 1b MAD study of ITMN-191 in combination with low dose ritonavir in HCV patients in the thi
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is the device," Nobel laureate Herbert Kroemer famously ... found at the junctures where layers of different ... the interfaces between layers of metal oxides are ... favorites as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Look inside ... hard-working items for the lab, from fluid handling to ... (GIS)—ready to ship when you order. , Preferred ... Pumps , from the L/S® model for precise flow ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced ... the Company issued new inducement stock options to,19 ... in,connection with its commercialization efforts in the United ... aggregate 119,200 shares of,common stock and are classified ...
... SectorWatch.biz announces the,availability of MarketStats on public ... today., Investors can view all of SectorWatch.biz ... -- Click on MarketStats, Today,s MarketStats on ... (OTC Bulletin Board: CVBT), Boston,Scientific Corp. (NYSE: ...
... - Atrium Innovations Inc.,(TSX: ATB) will hold its ... time on February 29, 2008. The call will ... and full year results issued earlier that,day. Participants ... numbers:,416-644-3420, 514-807-8791 or 800-731-5774 or via the Company,s ...
Cached Biology Technology:CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2Atrium Innovations to Hold 2007 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast on February 29 2
(Date:4/17/2014)... April 17, 2014The development of stem cell therapies to ... to characterize stem cell populations based on cell surface ... a new marker that is highly expressed in a ... blood, which they describe in an article in ... Ann Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... N.M. A credit-card-sized anthrax detection cartridge developed at ... business makes testing safer, easier, faster and cheaper. ... anthrax, is commonly found in soils all over the ... in both humans and animals. The bacteria can survive ... B. anthracis may occur through skin contact, ...
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... progress on their guarantee to protect global oceans from overfishing ... 15th June) in Science , the Zoological Society of ... by governments to protect the world,s oceans and shown that ... At the World Summit on Sustainable Development in ...
... A grasshopper,s change in diet to high-energy carbohydrates while ... releases carbon dioxide into the atmosphere, according to research ... . Grasshoppers like to munch on nitrogen-rich grass ... when spiders enter the picture, grasshoppers cope with the ...
... found a surprising connection between a key DNA-repair process and ... and other chronic conditions. The discovery promises to open up ... could ultimately yield novel treatments for a wide variety of ... it goes against current dogma about the role of DNA ...
Cached Biology News:A sea of broken promises 2Predators have outsized influence over habitats 2Scientists tie DNA repair to key cell signaling network 2
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... cytopathic effect inhibition assays, also known as ... assay measures the antibody's ability to neutralize ... types include; tissue culture supernatents; serum and ... unit is defined as the quantity of ...
... Yeast nitrogen base (YNB) is a base ... yeast media. YNB contains ammonium sulfate but does ... single-use pouches are available. Each pouch contains ... for Pichia media or 1000 ml of 10X ...
... Stem Cell Identification Kit. ... a substrate for the ... that is highly expressed ... cells, making ALDH an ...
Biology Products: